ImmuCell Corporation (ICCC) Gross margin 2017–2025
ImmuCell Corporation (ICCC) gross margin by fiscal year — reported gross profit divided by reported revenue.
41.4%FY2025 · since FY2017: 50.1% → 41.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 41.4% | +11.4 pp |
| FY2024 | 30.0% | +7.8 pp |
| FY2023 | 22.1% | -19.0 pp |
| FY2022 | 41.2% | -3.8 pp |
| FY2021 | 45.0% | +0.3 pp |
| FY2020 | 44.7% | -4.4 pp |
| FY2019 | 49.1% | +1.8 pp |
| FY2018 | 47.3% | -2.8 pp |
| FY2017 | 50.1% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice